The FDA's Molecular and Clinical Genetics Panel meets September 23 to review the premarket approval application for Galleri, the first multi-cancer early detection blood test to reach a full advisory committee review in the United States. GRAIL submitted the application in late January, and GRAIL's announcement of the advisory committee meeting confirmed the date.
The panel vote is a recommendation, not a decision. According to the FDA's meeting announcement for the panel, advisory committees make non-binding recommendations that the agency generally follows but is not legally bound to accept. The test is currently sold in the U.S. as a prescription-only laboratory test, so approval would change its regulatory status rather than introduce it.
The question the committee will actually weigh is narrower than the headline suggests. Galleri's submission rests on how well the test finds cancer and how often it is wrong, not on whether finding those cancers earlier helps people live longer. No trial has yet demonstrated a mortality benefit.
The Numbers the Committee Will Examine
The application draws on 25,490 consented participants with one year of follow-up from the U.S.-based PATHFINDER 2 study, plus data from more than 70,000 participants in the intervention arm of the first screening round of the NHS-Galleri trial in the United Kingdom. An account of the submission's supporting studies notes that the FDA designated Galleri a breakthrough device in 2018.
Results from the full PATHFINDER 2 results presented at ASCO, covering the entire 35,878-participant cohort, showed a positive predictive value of 60.3%, meaning roughly three in five people with a positive result were confirmed to have cancer. Specificity was 99.6%, putting the false positive rate below 0.4%.
Sensitivity is where the picture gets more complicated, and it is the figure most likely to draw questions. Across all cancers, episode sensitivity, the ability to detect cancer confirmed within 12 months of the blood draw, was 39.3%. That means the test missed a majority of cancers confirmed in that window. For the 12 cancers responsible for two-thirds of U.S. cancer deaths, sensitivity was 69.8%.
GRAIL reported that adding Galleri to recommended screening increased screen-detected cancers by up to 6.5-fold, and that 70.9% of the newly detected cancers were stage I through III. The company has framed the case around unmet need, arguing that the current standard in cancer screening leaves most cancers with no recommended test at all.
The Evidence Question Behind the Vote
Screening tests are judged on a different standard than diagnostic ones, and that standard is the crux here. A test can find more cancers, find them earlier, and still fail to reduce deaths, because some detected cancers would never have caused harm and some aggressive ones progress regardless of when they are found. Cancer screening history contains several examples of that pattern.
PATHFINDER 2 is a single-arm interventional study. It measures how the test performs, not what happens to people who use it compared with people who do not. The NHS-Galleri trial is randomized and controlled, but the data submitted covers only the first screening round, and its mortality and stage-shift endpoints are expected years from now.
The 39.3% overall sensitivity also carries a counseling implication. A negative Galleri result does not mean a person is cancer-free, and the test is explicitly intended to be added to guideline-recommended screening rather than to replace mammography, colonoscopy, cervical screening or lung CT.
There is a behavioral risk attached to that. If patients treat a negative blood test as reassurance and defer a colonoscopy or mammogram, the net effect of adding the test could be negative for those individuals.
False positives are uncommon at under 0.4%, and GRAIL reported low rates of invasive follow-up procedures in the trial. But at population scale, a small percentage becomes a large number of scans, biopsies and weeks of uncertainty, and the panel is expected to weigh that trade-off directly.
MedicalDaily previously reported on the FDA review and what approval could mean for adults over 50. What is new is that a review date now exists and the evidence package is public enough to be argued over.
Reasonable Expectations for Patients Considering the Test
Nobody should change or skip a recommended screening based on this news. The clearest practical guidance in GRAIL's own materials is that Galleri is designed as an addition to standard screening, and every major guideline for breast, colorectal, cervical, and lung cancer remains unchanged.
Cost and coverage are the near-term barriers. Galleri has been sold out of pocket at roughly $950, and Medicare does not currently cover multi-cancer early detection tests. Congress has considered legislation creating a Medicare benefit category contingent on FDA approval, which is part of why the approval decision carries financial weight beyond the test itself.
Anyone weighing the test should ask a clinician three things: what a positive result would trigger in terms of imaging and biopsies, what a negative result does and does not rule out, and whether their family history or symptoms point toward a targeted workup instead.
The test is also not a substitute for evaluating symptoms. Anyone with unexplained weight loss, persistent pain, bleeding, or a lump needs a diagnostic workup regardless of any screening result, because screening tests are designed for people without symptoms and perform differently in people who have them.
What remains unknown is how the panel will vote, whether the FDA will follow that recommendation, what indication and labeling any approval would carry, and when NHS-Galleri mortality data will arrive. The meeting materials, including the FDA's own review memo, are typically posted publicly shortly before the panel convenes, and those documents usually reveal where the agency's reviewers disagree with the sponsor.
Key Questions Answered
What happens on September 23? The FDA's Molecular and Clinical Genetics Panel reviews the premarket approval application and votes. The vote advises the agency; it does not approve the test.
Is Galleri available now? Yes, as a prescription laboratory test. FDA approval would change its regulatory status, not create first-time availability.
How accurate is it? In PATHFINDER 2, positive predictive value was 60.3% and specificity 99.6%. Overall episode sensitivity was 39.3%, rising to 69.8% for the 12 deadliest cancers.
Does a negative result mean no cancer? No. The test missed a majority of cancers confirmed within a year in the trial, which is why it is positioned as an addition to standard screening.
Has it been shown to save lives? Not yet. No trial has demonstrated a mortality benefit. The randomized NHS-Galleri trial's mortality endpoint is still years away.
Does insurance cover it? Generally no. It has been sold out of pocket, and Medicare does not currently cover multi-cancer early detection tests.
Should anyone stop routine screening? No. Guidelines for breast, colorectal, cervical and lung cancer screening are unchanged.
